Otis Brawley, the chief medical officer of the American Cancer Society, had been one big naysayer, arguing that previous studies of Provenge didn't offer a clear benefit.
Mr. ASTON-REESE: I'm not a naysayer or anything but I just think that we could be on that - just on the precipice looking down into the abyss right here.